Stocks · Sector
Healthcare Stocks - Prices & Analysis (1,175)
| Company | Ticker | Price | Mkt cap | P/E | Div yield |
|---|---|---|---|---|---|
| Recursion Pharmaceuticals, Inc. | RXRX | $3.63 | $1.95B | — | |
| GH Research PLC | GHRS | $28.23 | $1.94B | — | |
| Vir Biotechnology, Inc. | VIR | $11.39 | $1.93B | — | |
| Stoke Therapeutics, Inc. | STOK | $29.81 | $1.92B | — | |
| Astrana Health, Inc. | ASTH | $38.47 | $1.91B | 46.4 | — |
| Alvotech | ALVO | $5.32 | $1.90B | — | |
| Braveheart Bio, Inc. | BRVE | $26.74 | $1.89B | — | |
| P3 Health Partners Inc. | PIII | $9.35 | $1.87B | — | |
| Surgery Partners, Inc. | SGRY | $14.26 | $1.87B | — | |
| Lakefront Biotherapeutics NV | LKFT | $28.49 | $1.87B | 2.8 | — |
| Immunocore Holdings plc | IMCR | $36.13 | $1.86B | — | |
| Damora Therapeutics, Inc. | DMRA | $30.06 | $1.86B | — | |
| LeMaitre Vascular, Inc. | LMAT | $80.67 | $1.84B | 28.2 | 1.24% |
| COMPASS Pathways plc | CMPS | $13.27 | $1.84B | — | |
| Personalis, Inc. | PSNL | $17.20 | $1.84B | — | |
| Syndax Pharmaceuticals, Inc. | SNDX | $20.56 | $1.84B | — | |
| Taysha Gene Therapies, Inc. | TSHA | $5.60 | $1.82B | — | |
| Inspire Medical Systems, Inc. | INSP | $63.08 | $1.82B | 13.7 | — |
| Dynavax Technologies Corporation | DVAX | $15.50 Feb 10, 2026 | $1.82B | — | |
| Sonida Senior Living, Inc. | SNDA | $37.69 | $1.81B | — | |
| Intellia Therapeutics, Inc. | NTLA | $12.74 | $1.79B | — | |
| Inhibrx Biosciences, Inc. | INBX | $121.17 | $1.78B | — | |
| Freenome, Inc. | FRNM | $16.31 | $1.75B | — | |
| BioLife Solutions, Inc. | BLFS | $35.25 | $1.72B | 35.3 | — |
| Septerna, Inc. | SEPN | $36.75 | $1.72B | — | |
| Tyra Biosciences, Inc. | TYRA | $28.65 | $1.71B | — | |
| Novavax, Inc. | NVAX | $10.22 | $1.69B | — | |
| Fortrea Holdings Inc. | FTRE | $17.70 | $1.68B | — | |
| AnaptysBio, Inc. | ANAB | $56.80 | $1.68B | — | |
| RAPT Therapeutics Inc | RAPT | $58.01 Mar 6, 2026 | $1.68B | — | |
| Eton Pharmaceuticals, Inc. | ETON | $58.45 | $1.67B | 149.9 | — |
| Avalyn Pharma Inc. | AVLN | $37.39 | $1.66B | — | |
| Ascentage Pharma Group Internat | AAPG | $17.62 | $1.65B | — | |
| ANI Pharmaceuticals, Inc. | ANIP | $71.23 | $1.64B | 15.7 | — |
| Forte Biosciences, Inc. | FBRX | $76.99 Aug 28, 2026 | $1.63B | — | |
| SL Science Holding Limited | SLBT | $2.88 | $1.61B | — | |
| LB Pharmaceuticals Inc | LBRX | $49.34 | $1.59B | — | |
| Omnicell, Inc. | OMCL | $34.37 | $1.56B | 40.9 | — |
| Xeris Biopharma Holdings, Inc. | XERS | $8.53 | $1.56B | — | |
| Phibro Animal Health Corporation | PAHC | $38.25 | $1.55B | 15.9 | 1.24% |
| Innoviva, Inc. | INVA | $21.33 | $1.54B | 5.0 | — |
| Ardent Health, Inc. | ARDT | $10.91 | $1.54B | 19.8 | — |
| Bicara Therapeutics Inc. | BCAX | $23.17 | $1.53B | — | |
| Latigo Biotherapeutics, Inc. | LTGO | $23.04 | $1.53B | — | |
| ArriVent BioPharma, Inc. | AVBP | $30.95 | $1.53B | — | |
| Absci Corporation | ABSI | $8.82 | $1.51B | — | |
| Ultragenyx Pharmaceutical Inc. | RARE | $15.30 | $1.51B | — | |
| Aktis Oncology, Inc. | AKTS | $27.05 | $1.50B | — | |
| Schrödinger, Inc. | SDGR | $20.09 | $1.50B | — | |
| Healthcare Services Group, Inc. | HCSG | $21.82 | $1.50B | 12.8 | — |
Recursion Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.95B
- P/E
- unprofitable
GH Research PLC
Healthcare / Biotechnology
- Market Cap
- $1.94B
- P/E
- unprofitable
Vir Biotechnology, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.93B
- P/E
- unprofitable
Stoke Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.92B
- P/E
- unprofitable
Astrana Health, Inc.
Healthcare / Medical Care Facilities
- Market Cap
- $1.91B
- P/E
- 46.4
Alvotech
Healthcare / Drug Manufacturers - Specialty & Generic
- Market Cap
- $1.90B
- P/E
- unprofitable
Braveheart Bio, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.89B
- P/E
- unprofitable
P3 Health Partners Inc.
Healthcare / Medical Care Facilities
- Market Cap
- $1.87B
- P/E
- unprofitable
Surgery Partners, Inc.
Healthcare / Medical Care Facilities
- Market Cap
- $1.87B
- P/E
- unprofitable
Lakefront Biotherapeutics NV
Healthcare / Biotechnology
- Market Cap
- $1.87B
- P/E
- 2.8
Immunocore Holdings plc
Healthcare / Biotechnology
- Market Cap
- $1.86B
- P/E
- unprofitable
Damora Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.86B
- P/E
- unprofitable
LeMaitre Vascular, Inc.
Healthcare / Medical Instruments & Supplies
- Market Cap
- $1.84B
- P/E
- 28.2
- Dividend Yield
- 1.24%
COMPASS Pathways plc
Healthcare / Medical Care Facilities
- Market Cap
- $1.84B
- P/E
- unprofitable
Personalis, Inc.
Healthcare / Diagnostics & Research
- Market Cap
- $1.84B
- P/E
- unprofitable
Syndax Pharmaceuticals, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.84B
- P/E
- unprofitable
Taysha Gene Therapies, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.82B
- P/E
- unprofitable
Inspire Medical Systems, Inc.
Healthcare / Medical Devices
- Market Cap
- $1.82B
- P/E
- 13.7
Dynavax Technologies Corporation
Healthcare / Drug Manufacturers - Specialty & Generic
- Market Cap
- $1.82B
- P/E
- unprofitable
Sonida Senior Living, Inc.
Healthcare / Medical Care Facilities
- Market Cap
- $1.81B
- P/E
- unprofitable
Intellia Therapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.79B
- P/E
- unprofitable
Inhibrx Biosciences, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.78B
- P/E
- unprofitable
Freenome, Inc.
Healthcare / Diagnostics & Research
- Market Cap
- $1.75B
- P/E
- unprofitable
BioLife Solutions, Inc.
Healthcare / Medical Instruments & Supplies
- Market Cap
- $1.72B
- P/E
- 35.3
Septerna, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.72B
- P/E
- unprofitable
Tyra Biosciences, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.71B
- P/E
- unprofitable
Novavax, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.69B
- P/E
- unprofitable
Fortrea Holdings Inc.
Healthcare / Biotechnology
- Market Cap
- $1.68B
- P/E
- unprofitable
AnaptysBio, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.68B
- P/E
- unprofitable
RAPT Therapeutics Inc
Healthcare / Biotechnology
- Market Cap
- $1.68B
- P/E
- unprofitable
Eton Pharmaceuticals, Inc.
Healthcare / Drug Manufacturers - Specialty & Generic
- Market Cap
- $1.67B
- P/E
- 149.9
Avalyn Pharma Inc.
Healthcare / Biotechnology
- Market Cap
- $1.66B
- P/E
- unprofitable
Ascentage Pharma Group Internat
Healthcare / Biotechnology
- Market Cap
- $1.65B
- P/E
- unprofitable
ANI Pharmaceuticals, Inc.
Healthcare / Drug Manufacturers - Specialty & Generic
- Market Cap
- $1.64B
- P/E
- 15.7
Forte Biosciences, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.63B
- P/E
- unprofitable
SL Science Holding Limited
Healthcare / Biotechnology
- Market Cap
- $1.61B
- P/E
- unprofitable
LB Pharmaceuticals Inc
Healthcare / Biotechnology
- Market Cap
- $1.59B
- P/E
- unprofitable
Omnicell, Inc.
Healthcare / Health Information Services
- Market Cap
- $1.56B
- P/E
- 40.9
Xeris Biopharma Holdings, Inc.
Healthcare / Drug Manufacturers - Specialty & Generic
- Market Cap
- $1.56B
- P/E
- unprofitable
Phibro Animal Health Corporation
Healthcare / Drug Manufacturers - Specialty & Generic
- Market Cap
- $1.55B
- P/E
- 15.9
- Dividend Yield
- 1.24%
Innoviva, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.54B
- P/E
- 5.0
Ardent Health, Inc.
Healthcare / Medical Care Facilities
- Market Cap
- $1.54B
- P/E
- 19.8
Bicara Therapeutics Inc.
Healthcare / Biotechnology
- Market Cap
- $1.53B
- P/E
- unprofitable
Latigo Biotherapeutics, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.53B
- P/E
- unprofitable
ArriVent BioPharma, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.53B
- P/E
- unprofitable
Absci Corporation
Healthcare / Biotechnology
- Market Cap
- $1.51B
- P/E
- unprofitable
Ultragenyx Pharmaceutical Inc.
Healthcare / Biotechnology
- Market Cap
- $1.51B
- P/E
- unprofitable
Aktis Oncology, Inc.
Healthcare / Biotechnology
- Market Cap
- $1.50B
- P/E
- unprofitable
Schrödinger, Inc.
Healthcare / Health Information Services
- Market Cap
- $1.50B
- P/E
- unprofitable
Healthcare Services Group, Inc.
Healthcare / Medical Care Facilities
- Market Cap
- $1.50B
- P/E
- 12.8
Showing 301–350 of 1,175 · ranked by market capitalization
Where the trailing year was a loss, P/E appears as “unprofitable”; a dash is missing data.